The aim of percutaneous coronary intervention (PCI) is to optimise coronary and cardial status, and thus improve short-and long-term outcomes. It is known from large Western databases that stent implantation is performed during 77-85% of coronary interventions, which means hundreds of thousands of patients with new stent every year. The majority of patients need to take dual platelet aggregation inhibitor, namely acetyilsalicylic acid and thienopyridin - most often clopidrogel - following stent implantation. It presents a major therapeutic dilemma when these patients need noncardiac surgery. First, the surgery should be performed with the least blood loss possible, which would be optimally achieved by suspension of the platelet aggregation inhibitor therapy that cannot be stopped during the critical period after stent implantation. Second, stent thrombosis should be avoided, which can only be achieved if platelet aggregation inhibitor therapy is continued. The aim of our paper is to summarise the current professional guidelines and the current risk estimation in the perioperative management of patients with coronary stent. In the second part of the article, we summarise the preoperative preparation of the patient, assessment of coronary status and cardial medication, and the optimal time and location of the surgery. We present the decision principles regarding the risks of perioperative bleeding and stent thrombosis, and the need to continue platelet aggregation inhibitor therapy.
|Translated title of the contribution||Perioperative management of patients with coronary stent undergoing noncardiac surgical procedures - Part II. - Algorythm of emergency and perioperative treatment decisions|
|Number of pages||9|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Nov 1 2011|
ASJC Scopus subject areas